MDT

87.15

-1.56%↓

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

Home・Akciju saraksts・Microbot Medical Inc

Microbot Medical Inc

Atvērts

2.64 7.76

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.42

Max

2.64

Galvenie mērījumi
By Trading Economics
Ienākumi	113K -3.5M
Darbinieki	20
EBITDA	-561K -4.1M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+219.15% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 12. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-11M 158M
Iepriekšējā atvēršanas cena	-5.12
Iepriekšējā slēgšanas cena	2.64

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

2.52 / 2.57 Atbalsts un pretestība

Microbot Medical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB: Higher Energy Prices to Raise Production, Consumer Costs

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

2026. g. 9. apr. 23:44 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

2026. g. 9. apr. 23:34 UTC

Tirgus saruna

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

2026. g. 9. apr. 23:14 UTC

Tirgus saruna

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

2026. g. 9. apr. 23:14 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 9. apr. 23:07 UTC

Tirgus saruna

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

2026. g. 9. apr. 22:54 UTC

Tirgus saruna

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

2026. g. 9. apr. 22:31 UTC

Galvenie ziņu notikumi

Trump on Truth Social: 'That Is Not the Agreement We Have!'

2026. g. 9. apr. 22:31 UTC

Galvenie ziņu notikumi

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

2026. g. 9. apr. 20:57 UTC

Galvenie ziņu notikumi

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

2026. g. 9. apr. 20:55 UTC

Peļņas

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

2026. g. 9. apr. 20:55 UTC

Peļņas

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

2026. g. 9. apr. 20:55 UTC

Peļņas

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

2026. g. 9. apr. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 9. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. apr. 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

2026. g. 9. apr. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

2026. g. 9. apr. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Rowan Digital Infrastructure Announces Strategic Recapitalization

2026. g. 9. apr. 20:25 UTC

Iegādes, apvienošanās, pārņemšana

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

2026. g. 9. apr. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 9. apr. 19:30 UTC

Galvenie ziņu notikumi

How Digital Currencies Have Helped Iran -- WSJ

Salīdzinājums

Cenas izmaiņa

Microbot Medical Inc Prognoze

Cenas mērķis

By TipRanks

219.15% augšup

Prognoze 12 mēnešiem

Vidējais 7.5 USD 219.15%

Augstākais 12 USD

Zemākais 5 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Microbot Medical Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Microbot Medical Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

2.52 / 2.57Atbalsts un pretestība

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bullish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.